Advanced Search
Contact | Corporate | Help

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Sponsors:
  • Massachusetts General Hospital
  • Genentech
  • Sanofi-Aventis
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
Phases:
  • Phase II
IndicationsAcronym:
  • Biliary Tract Adenocarcinoma
  • Gallbladder Adenocarcinoma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Bevacizumab
  • Drug: Gemcitabine
  • Drug: Oxaliplatin
Enrollment:
37

Additional information about NCT00361231.


SourceSolution © 2008-2012